Zachariah Serber - 22 Feb 2022 Form 4 Insider Report for Zymergen Inc. (ZY)

Role
Chief Science Officer, Director
Signature
/s/ Natalie Dement, attorney-in-fact
Issuer symbol
ZY
Transactions as of
22 Feb 2022
Net transactions value
-$5,568
Form type
4
Filing time
24 Feb 2022, 15:53:26 UTC
Previous filing
16 Feb 2022
Next filing
01 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZY Common Stock Sale $5,568 -1,424 -0.06% $3.91 2,373,491 22 Feb 2022 Direct F1
holding ZY Common Stock 40,000 22 Feb 2022 See Footnote F2
holding ZY Common Stock 40,000 22 Feb 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2021 that provides for the sale of up to 250,000 shares over the next ten (10) months, which started January 24, 2022.
F2 Held by the Rorik Serber 2021 Irrevocable Trust.
F3 Held by spouse as custodian for children under the California Uniform Transfer to Minors Act.